Pregled bibliografske jedinice broj: 1274317
Methodology for clinical genotyping of CYP2D6 and CYP2C19
Methodology for clinical genotyping of CYP2D6 and CYP2C19 // Translational Psychiatry, 11 (2021), 1; 596, 9 doi:10.1038/s41398-021-01717-9 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1274317 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Methodology for clinical genotyping of CYP2D6 and
CYP2C19
Autori
Carvalho Henriques, Beatriz ; Buchner, Avery ; Hu, Xiuying ; Wang, Yabing ; Yavorskyy, Vasyl ; Wallace, Keanna ; Dong, Rachael ; Martens, Kristina ; Carr, Michael S. ; Behroozi Asl, Bahareh ; Hague, Joshua ; Sivapalan, Sudhakar ; Maier, Wolfgang ; Dernovsek, Mojca Z. ; Henigsberg, Neven ; Hauser, Joanna ; Souery, Daniel ; Cattaneo, Annamaria ; Mors, Ole ; Rietschel, Marcella ; Pfeffer, Gerald ; Hume, Stacey ; Aitchison, Katherine J.
Izvornik
Translational Psychiatry (2158-3188) 11
(2021), 1;
596, 9
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Genotyping ; CYP2D6 ; CYP2C19
Sažetak
Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, and guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology for clinical genotyping of CYP2D6 and CYP2C19. The aim of this paper was to cross- validate multiple technologies for genotyping CYP2D6 and CYP2C19 against each other, and to contribute to feasibility for clinical implementation by providing an enhanced range of assay options, customizable automated translation of data into haplotypes, and a workflow algorithm. AmpliChip CYP450 and some TaqMan single nucleotide variant (SNV) and copy number variant (CNV) data in the Genome-based therapeutic drugs for depression (GENDEP) study were used to select 95 samples (out of 853) to represent as broad a range of CYP2D6 and CYP2C19 genotypes as possible. These 95 included a larger range of CYP2D6 hybrid configurations than have previously been reported using inter-technology data. Genotyping techniques employed were: further TaqMan CNV and SNV assays, xTAGv3 Luminex CYP2D6 and CYP2C19, PharmacoScan, the Ion AmpliSeq Pharmacogenomics Panel, and, for samples with CYP2D6 hybrid configurations, long- range polymerase chain reactions (L-PCRs) with Sanger sequencing and Luminex. Agena MassARRAY was also used for CYP2C19. This study has led to the development of a broader range of TaqMan SNV assays, haplotype phasing methodology with TaqMan adaptable for other technologies, a multiplex genotyping method for efficient identification of some hybrid haplotypes, a customizable automated translation of SNV and CNV data into haplotypes, and a clinical workflow algorithm.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče
Profili:
Neven Henigsberg
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE